Buy These 4 Value Stocks as Middle East Tensions Rattle Markets Again
Middle East tensions are rattling markets, putting Nexa Resources, Stone, General Motors and Invesco in focus as low-P/CF value picks.
IVZ - Invesco Ltd.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$30.81
DETAILS
HIGH:
$34.50
LOW:
$28.00
MEDIAN:
$31.00
CONSENSUS:
$30.81
UPSIDE:
7.82%
Stock News
Is Invesco (IVZ) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
What This Invesco Insider Move Signals With the Stock Up 63%
The transaction involved 26,002 shares withheld to satisfy tax obligations at a value of $702,000 based on the $27.01 per-share price. The disposition reduced the insider's direct common stock position by 17%.
Here's Why Invesco (IVZ) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Invesco Ltd. Announces June 30, 2026 Assets Under Management
ATLANTA, July 10, 2026 /PRNewswire/ -- Invesco Ltd. (NYSE: IVZ)1, a leading global asset management firm announced today preliminary month-end assets under management (AUM) of $2,470.3 billion, an increase of 0.7% versus previous month-end.
Invesco Pharmaceuticals ETF vs State Street Biotech ETF: Which Fund Is the Better Buy in 2026?
Invesco Pharmaceuticals ETF offers a higher dividend yield and lower five-year beta than State Street SPDR S&P Biotech ETF State Street SPDR S&P Biotech ETF holds 155 securities compared to 30 in Invesco Pharmaceuticals ETF Invesco Pharmaceuticals ETF has experienced a significantly smaller max drawdown of 17.5% over the last five years, compared to 54% for State Street SPDR S&P Biotech ETF
Invesco Pharmaceuticals ETF or First Trust Biotech Fund: Which Drug Maker-Focused Fund Should You Buy in 2026?
Invesco Pharmaceuticals ETF has a higher 5-year growth total of $1,563 compared to $1,480 for First Trust NYSE Arca Biotechnology Index Fund First Trust NYSE Arca Biotechnology Index Fund is more affordable with a 0.55% expense ratio while Invesco Pharmaceuticals ETF charges 0.57% Invesco Pharmaceuticals ETF experienced a lower 5-year maximum drawdown of 17.50% compared to 29.90% for the First Trust fund
Gold had a rough Q2, but central bank demand will push prices higher through 2026 – Invesco
While Q2 was the worst quarter for gold in 12 years, with spiking energy prices raising inflation expectations and introducing the possibility of rate hikes, central bank demand will help gold finish the year on a positive note, according to the new quarterly gold outlook from Invesco.
Which Healthcare ETF Is the Better Buy: Invesco's IBBQ or State Street's XPH?
Invesco Nasdaq Biotechnology ETF offers a lower expense ratio and a higher trailing dividend yield than State Street SPDR S&P Pharmaceuticals ETF. State Street SPDR S&P Pharmaceuticals ETF has delivered a higher 1-year total return and experienced a less severe maximum drawdown than Invesco Nasdaq Biotechnology ETF.
Should You Invest in the Invesco Bloomberg Financial Data Providers ETF (FDIQ)?
If you're interested in broad exposure to the Financials - Regional Banks segment of the equity market, look no further than the Invesco Bloomberg Financial Data Providers ETF (FDIQ), a passively managed exchange traded fund launched on November 1, 2011.
Invesco (IVZ) is a Top-Ranked Value Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Northern Trust Appointed to Support Invesco's New Index-Tracking Mutual Fund Range
DUBLIN--(BUSINESS WIRE)--Northern Trust (Nasdaq: NTRS) today announced it has been appointed by Invesco to provide administration, custody and depositary services for its new Irish-domiciled index tracking mutual fund range, Invesco Markets V ICAV. Invesco is a U.S. asset management company serving clients in more than 120 countries. Headquartered in Atlanta, Georgia, the firm has US$2.45 trillion in assets under management across public, private, active, and passive investments (as of 31 May 2.
State Street Health Care ETF Tops Invesco Pharma on Cost and Size
State Street Health Care Select Sector SPDR ETF offers a significantly lower expense ratio and far greater assets under management than Invesco Pharmaceuticals ETF. Invesco's ETF focuses exclusively on 29 pharmaceutical companies, whereas the SPDR fund provides broader exposure across the healthcare sector.
Vanguard S&P 500 Growth vs. Invesco SmallCap Revenue: How Do These ETFs Stack Up?
Vanguard S&P 500 Growth ETF offers a significantly lower expense ratio than Invesco S&P SmallCap 600 Revenue ETF. Invesco's ETF has delivered higher one-year total returns but lower five-year growth than the Vanguard fund.
Top Invesco Analyst: The AI Trade That “Lifted All Boats” Is Over. Now Profitability Decides Winners As “Capacity Will Catch Up”
Invesco's Fiona Lim says the AI-fueled semiconductor surge is shifting from a broad, momentum-driven rally to a tougher phase where stock picking and profitability will separate winners from laggards.
Here's Why Invesco (IVZ) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Should You Buy the Invesco QQQ ETF After the Recent Nasdaq Sell-Off? History Offers a Crystal-Clear Answer.
The Nasdaq-100 has a high degree of exposure to some of America's largest technology stocks. The Invesco QQQ ETF tracks the Nasdaq-100 and is currently down 3% from its all-time high.
Looking for an Aerospace and Defense ETF? Compare Funds From Invesco and First Trust
Invesco Aerospace & Defense ETF has a longer track record and significantly more assets under management than First Trust Indxx Aerospace & Defense ETF Both funds lean heavily into the industrials sector but First Trust Indxx Aerospace & Defense ETF maintains a higher allocation to technology stocks Invesco Aerospace & Defense ETF has delivered a higher total return over the past year with less severe price pullbacks
Are You Looking for a High-Growth Dividend Stock?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Invesco (IVZ) have what it takes?
Invesco Ltd. to Announce Second Quarter 2026 Results
ATLANTA, July 1, 2026 /PRNewswire/ -- Invesco Ltd. (NYSE: IVZ) will release its second quarter 2026 results on Tuesday, July 28, 2026.
Price Targets
Invesco price target raised to $31 from $26 at Barclays
$31.00
(was $28.40)
Barclays
Invesco price target raised to $32 from $31 at Evercore ISI
$32.00
(was $29.07)
Evercore ISI
Invesco price target raised to $31 from $28 at Evercore ISI
$31.00
(was $27.79)
Evercore ISI
Invesco price target raised to $30 from $27 at Goldman Sachs
$30.00
(was $25.88)
Alexander Blostein
·
Goldman Sachs
Invesco price target raised to $26 from $24 at Barclays
$26.00
(was $25.88)
Barclays
Invesco price target lowered to $31 from $33 at RBC Capital
$31.00
(was $24.95)
Kenneth Lee
·
RBC Capital
Invesco price target lowered to $27 from $29 at Evercore ISI
$27.00
(was $23.63)
Evercore ISI
Invesco price target lowered to $28 from $32 at BMO Capital
$28.00
(was $23.63)
BMO Capital
Invesco price target lowered to $33 from $35 at RBC Capital
$33.00
(was $27.77)
Kenneth Lee
·
RBC Capital
Invesco price target raised to $34.50 from $33.50 at TD Cowen
$34.50
(was $27.27)
Cowen & Co.
Invesco price target raised to $31 from $27 at Argus
$31.00
(was $27.25)
Stephen Biggar
·
Argus Research
Invesco price target raised to $29.50 from $28.75 at Goldman Sachs
$29.50
(was $27.16)
Goldman Sachs
Invesco price target lowered to $29 from $30 at Barclays
$29.00
(was $27.16)
Barclays
Invesco price target raised to $29 from $28 at Morgan Stanley
$29.00
(was $28.40)
Morgan Stanley
RBC Capital Upgrades Invesco (IVZ) to Outperform
$35.00
(was $28.95)
Kenneth Lee
·
RBC Capital
Invesco price target raised to $28.75 from $28.25 at Goldman Sachs
$28.75
(was $28.25)
Alexander Blostein
·
Goldman Sachs
Invesco price target raised to $30 from $28 at Barclays
$30.00
(was $28.25)
Benjamin Budish
·
Barclays
Invesco price target raised to $28.25 from $25.50 at Goldman Sachs
$28.25
(was $28.16)
Alexander Blostein
·
Goldman Sachs
Invesco price target raised to $28 from $27 at Morgan Stanley
$28.00
(was $26.82)
Morgan Stanley
Deutsche upgrades Invesco to Buy on better organic growth
$31.00
(was $26.03)
Deutsche Bank